In EASL guidelines, AFP significantly reflects tumor biology, invasion, stage, and aggression and is a revealing marker in predicting post-transplant survival.26 Furthermore, high AFP (≥200 ng/mL) is associated with increased microvascular invasion and high mortality in patients with HCC receiving sorafenib treatment. This evidence concerns the gene AFP and neoplasm.